Literature DB >> 12034695

Retinopathy of prematurity: recent advances in our understanding.

C M Wheatley1, J L Dickinson, D A Mackey, J E Craig, M M Sale.   

Abstract

Retinopathy of prematurity (ROP) has been recognised as an important cause of childhood visual impairment and blindness since the 1940s when improved facilities and treatment increased the survival rate of premature infants. Although its incidence and severity have been decreasing in developed countries over the past two decades, both are increasing in developing nations. ROP is consequently targeted as an important but avoidable disease. This review provides an updated summary and discussion of much of the work that has been produced through population, animal, cell culture, and genetic research. The authors examine the prevalence, risk factors, and possible causes of the disease with a particular focus on genetic studies. They conclude that while significant reductions in the disease have occurred in developed countries, further research is required to fully understand and prevent the disease. In the meantime, development and implementation of appropriate screening and treatment strategies will be critical in reducing blindness in developing countries.

Entities:  

Mesh:

Year:  2002        PMID: 12034695      PMCID: PMC1771164          DOI: 10.1136/bjo.86.6.696

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  89 in total

1.  X-linked recessive familial exudative vitreoretinopathy.

Authors:  D A Plager; I K Orgel; F D Ellis; M Hartzer; M T Trese; B S Shastry
Journal:  Am J Ophthalmol       Date:  1992-08-15       Impact factor: 5.258

2.  Risk factors associated with retinopathy of prematurity (ROP) in northern Jutland, Denmark 1990-1993.

Authors:  H Nødgaard; H Andreasen; H Hansen; H T Sørensen
Journal:  Acta Ophthalmol Scand       Date:  1996-06

3.  Norrie disease in a family with a manifesting female carrier.

Authors:  K B Sims; A R Irvine; W V Good
Journal:  Arch Ophthalmol       Date:  1997-04

4.  An international classification of retinopathy of prematurity. II. The classification of retinal detachment. The International Committee for the Classification of the Late Stages of Retinopathy of Prematurity.

Authors: 
Journal:  Arch Ophthalmol       Date:  1987-07

5.  Does candidemia predict threshold retinopathy of prematurity in extremely low birth weight (</=1000 g) neonates?

Authors:  M G Karlowicz; P J Giannone; J Pestian; A L Morrow; J Shults
Journal:  Pediatrics       Date:  2000-05       Impact factor: 7.124

6.  Eight-year outcome in infants with birth weight of 500 to 999 grams: continuing regional study of 1979 and 1980 births. Victorian Infant Collaborative Study Group.

Authors: 
Journal:  J Pediatr       Date:  1991-05       Impact factor: 4.406

7.  Childhood blindness.

Authors:  P G Steinkuller; L Du; C Gilbert; A Foster; M L Collins; D K Coats
Journal:  J AAPOS       Date:  1999-02       Impact factor: 1.220

8.  Poor postnatal weight gain: a risk factor for severe retinopathy of prematurity.

Authors:  D K Wallace; J A Kylstra; S J Phillips; J G Hall
Journal:  J AAPOS       Date:  2000-12       Impact factor: 1.220

9.  Blindness in infants and young children.

Authors:  E M Hatfield
Journal:  Sight Sav Rev       Date:  1972

10.  Mutations in the Norrie disease gene.

Authors:  D E Schuback; Z Y Chen; I W Craig; X O Breakefield; K B Sims
Journal:  Hum Mutat       Date:  1995       Impact factor: 4.878

View more
  21 in total

1.  Dopamine is an indicator but not an independent risk factor for grade 3 retinopathy of prematurity in extreme low birthweight infants.

Authors:  K Allegaert; V Cossey; G Naulaers; C Vanhole; H Devlieger; I Casteels
Journal:  Br J Ophthalmol       Date:  2004-02       Impact factor: 4.638

2.  Inflammation and retinopathy of prematurity.

Authors:  Olaf Dammann
Journal:  Acta Paediatr       Date:  2010-04-16       Impact factor: 2.299

Review 3.  Genetic susceptibility to retinopathy of prematurity: the evidence from clinical and experimental animal studies.

Authors:  Gerd Holmström; Peter van Wijngaarden; Douglas J Coster; Keryn A Williams
Journal:  Br J Ophthalmol       Date:  2007-12       Impact factor: 4.638

Review 4.  Hereditary influences in oxygen-induced retinopathy in the rat.

Authors:  Peter van Wijngaarden; Helen M Brereton; Douglas J Coster; Keryn A Williams
Journal:  Doc Ophthalmol       Date:  2009-09-19       Impact factor: 2.379

5.  EphrinA1 inhibits vascular endothelial growth factor-induced intracellular signaling and suppresses retinal neovascularization and blood-retinal barrier breakdown.

Authors:  Tomonari Ojima; Hitoshi Takagi; Kiyoshi Suzuma; Hideyasu Oh; Izumi Suzuma; Hirokazu Ohashi; Daisuke Watanabe; Eri Suganami; Tomoaki Murakami; Masafumi Kurimoto; Yoshihito Honda; Nagahisa Yoshimura
Journal:  Am J Pathol       Date:  2006-01       Impact factor: 4.307

6.  Awareness and screening for retinopathy of prematurity among paediatricians in Nigeria.

Authors:  Om Uhumwangho; Yt Israel-Aina
Journal:  J West Afr Coll Surg       Date:  2013 Jul-Sep

Review 7.  Role of the retinal vascular endothelial cell in ocular disease.

Authors:  Arpita S Bharadwaj; Binoy Appukuttan; Phillip A Wilmarth; Yuzhen Pan; Andrew J Stempel; Timothy J Chipps; Eric E Benedetti; David O Zamora; Dongseok Choi; Larry L David; Justine R Smith
Journal:  Prog Retin Eye Res       Date:  2012-09-11       Impact factor: 21.198

8.  Expression and regulation of activated leukocyte cell adhesion molecule in human retinal vascular endothelial cells.

Authors:  Justine R Smith; Timothy J Chipps; Hoda Ilias; Yuzhen Pan; Binoy Appukuttan
Journal:  Exp Eye Res       Date:  2012-08-24       Impact factor: 3.467

Review 9.  Genetic susceptibility to advanced retinopathy of prematurity (ROP).

Authors:  Barkur S Shastry
Journal:  J Biomed Sci       Date:  2010-08-25       Impact factor: 8.410

10.  The genetic control of avascular area in mouse oxygen-induced retinopathy.

Authors:  Bliss E O'Bryhim; Jeff Radel; Stuart J Macdonald; R C Andrew Symons
Journal:  Mol Vis       Date:  2012-02-08       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.